Kuros Biosciences commenced an investigator-led multicenter study comparing MagnetOs bone graft substitute vs. autologous bone in posterolateral spinal fusion.
The blinded, controlled, randomized multicenter trial will enroll 100 patients in the Netherlands, starting in 2H18. The primary objective is to demonstrate non-inferiority in efficacy and safety of MagnetOs.
Earlier this quarter, Kuros received CE Mark approval for MagnetOs Putty as an osteoconductive, osteoinductive bone void filler inthe spine, extremities, pelvis, cranium, mandible and maxilla.
Sources: Kuros Biosciences; ORTHOWORLD Inc.
Kuros Biosciences commenced an investigator-led multicenter study comparing MagnetOs bone graft substitute vs. autologous bone in posterolateral spinal fusion.
The blinded, controlled, randomized multicenter trial will enroll 100 patients in the Netherlands, starting in 2H18. The primary objective is to demonstrate non-inferiority in efficacy...
Kuros Biosciences commenced an investigator-led multicenter study comparing MagnetOs bone graft substitute vs. autologous bone in posterolateral spinal fusion.
The blinded, controlled, randomized multicenter trial will enroll 100 patients in the Netherlands, starting in 2H18. The primary objective is to demonstrate non-inferiority in efficacy and safety of MagnetOs.
Earlier this quarter, Kuros received CE Mark approval for MagnetOs Putty as an osteoconductive, osteoinductive bone void filler inthe spine, extremities, pelvis, cranium, mandible and maxilla.
Sources: Kuros Biosciences; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.